Retractable Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 29, 2024. The company manufactures and markets safety syringes and other medical products. Its principal product is the VanishPoint syringe; it operates one reporting segment.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $43.6 million | $94.8 million |
| Gross profit / gross margin | $9.1 million / 20.9% | $28.3 million / 29.8% |
| Operating income (loss) | $(11.5) million | $(0.9) million |
| Net income (loss) | $(7.0) million | $5.1 million |
| Net income (loss) applicable to common shareholders | $(7.2) million; $(0.24) per share | $4.8 million; $0.15 per share |
| Cash from operating activities | $2.8 million | $16.8 million |
| Cash and cash equivalents at year-end | $12.7 million | $19.7 million |
| Investments in debt and equity securities | $34.6 million | $29.7 million |
| Total assets / stockholders’ equity | $179.7 million / $99.3 million | $195.7 million / $106.5 million |
Year-end current assets were $77.6 million and current liabilities were $9.4 million. Long-term debt was $1.5 million, including a $0.3 million current portion. Other long-term liabilities were $69.8 million, primarily deferred TIA funding recognized over the useful lives of funded assets; this is distinct from borrowing debt. The secured bank loan bears interest at 8.75% at year-end and matures in 2028.
Material changes versus the prior year
- Sales fell 54.0% and total unit sales fell 58.7%. Domestic revenue declined 33.7%; international revenue declined 78.9%.
- The U.S. government, a major COVID-19 vaccination customer in prior years, made no purchases in 2023, compared with $15.7 million of sales in 2022. International vaccination-related demand also dropped sharply.
- Gross margin contracted from 29.8% to 20.9%, while operating expenses decreased 29.2%. The company reported an $11.5 million operating loss, versus an $0.9 million loss in 2022.
- Non-operating results included a $10.5 million unrealized investment loss, partly offset by a $5.6 million realized gain on equity sales, $6.2 million of TIA-related other income, and $1.4 million of interest and other income. The 2022 results included $10.1 million of stock-based compensation expense, compared with none in 2023.
- Operating cash flow declined to $2.8 million. Investing activities used $10.8 million, including net purchases of securities; financing activities provided $0.9 million. Cash decreased $7.1 million. The company received an approximately $8 million state-tax refund in July 2023.
Outlook, commentary, and key risks
- Management gave no numerical revenue or earnings guidance. It expects adequate resources to meet short-term needs for at least 12 months from issuance of the financial statements and says foreseeable long-term liquidity needs can be met; it may reduce operating cash requirements if needed.
- Management attributes depressed domestic demand partly to customers holding vaccination-related inventory. It reports domestic unit sales rose in each quarter of 2023 for products used in vaccination, including flu shots, but says the timing and volume of future international orders are difficult to predict.
- COVID-related U.S. government orders and the TIA are not considered indicative of future operations. The TIA-funded expansion is complete; the agreement continues through June 30, 2030, including equipment maintenance, capacity availability, and U.S. government preference during a public health emergency.
- In 2023, Chinese manufacturers produced 88.4% of the company’s products, and international sales were 20.6% of revenue. Tariffs, trade restrictions, supplier or freight disruption, and the difficulty of replacing Chinese production could affect supply, costs, and profitability.
- Customer concentration is significant: four customers represented 61.3% of 2023 net sales. Syringes accounted for 78.3% of revenue. Management cites excess customer inventory, stronger competitors, and patent protection and expiration as material business risks.
- On February 5, 2024, the company initiated a voluntary U.S. recall of 477,600 EasyPoint needles from one lot due to possible detachment of the needle cannula, which could cause serious injury. The company estimated potential recall expense at approximately $116,000; the number of affected units still unused was not yet determined.
- A company lawsuit alleging malpractice and negligence against former counsel remained pending; defendants moved for summary judgment, with a hearing scheduled for April 9, 2024. Outcome and potential recovery are uncertain.
- Management reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified. The auditor issued an unqualified opinion on the financial statements; it identified rebate estimates as a critical audit matter.
Most important facts for investors to verify
- Whether domestic customer inventories clear and whether sales recover after the end of pandemic-related demand; assess reported unit-sales trends against subsequent results.
- Whether operating cash generation can support the expanded facilities’ ongoing costs, given lower sales, year-end cash of $12.7 million, and $34.6 million of market-valued investments.
- Investment portfolio composition and volatility: the company recorded a $10.5 million unrealized loss in 2023, and investments represented 19.3% of total assets.
- Recall progress, remaining affected inventory, actual costs, and any resulting claims or regulatory action.
- Exposure to Chinese manufacturing, customer concentration, patent/license terms and royalties, and the CEO’s 50.8% voting control.
- Potential distributor rebate credits: estimated unclaimed future credits were $2.2 million at December 31, 2023; the auditor treated rebate estimation as a critical audit matter.